Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis:

Background:Rituximab’s originator MabThera® or Rituxan® has demonstrated high efficacy in multiple sclerosis (MS). Because of the patent expiration, rituximab biosimilars have been developed. Howev...